Cancer drug developer Zentalis Pharmaceuticals recently surfaced with an $85 million round. The funding was a series C financing, an unusually late point for a drugmaker to make its public debut.
Evofem Biosciences’ gel in midstage clinical trials reduced the risk of chlamydia and gonorrhea infections compared to a placebo.
French pharmaceutical Sanofi will pay $2.5 billion to buy Synthorx, a San Diego biotech that expanded the genetic alphabet in a quest to treat cancer.
MEDICINE: Focus Put on Population of Frequent ER Users
Just 5% of patients account for roughly half of the nation’s health care spending. These “super users” cycle through emergency rooms.
PHARMA: Xenon Could Receive up to $1.7 Billion In Milestone Payments
Neurocrine Biosciences has plunked down $50 million upfront for a potential epilepsy treatment, the San Diego company’s second major licensing deal this year.
UDG Aims to Expand Footprint, Especially in West Coast
Carin Canale-Theakston founded Canale Communications. Her twin goals: build the largest life sciences communications firm on the West Coast.
Evofem Biosciences’ gel in mid-stage clinical trials reduced the risk of chlamydia and gonorrhea infections compared to a placebo, the San Diego company reported Dec. 2.
Co. Targets RSK2 Enzyme Often Found in Breast Cancers
Phoenix Molecular Designs is attacking advanced breast cancer in a new way — and with added funding.
More Than a Dozen Entities Invest in Preclinical Programs
Avidity Biosciences recently was awarded a $100 million series C round.
BIOTECH: Co. Aims for Transparency in Each Step
Truvian Sciences wants to run a battery of tests on only drops of blood. Its mobile lab is designed to return answers in 20 minutes.